Summary
SCYX Chart
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
JERSEY CITY, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that patient dosing has resumed in the Phase 3 MARIO study, which is an innovative study to investigate oral ibrexafungerp as a potential step-down antifungal therapy following IV echinocandin for invasive candidiasis, a life-threatening infection. The study had been on hold due to concerns about potential cross-contamination in light of draft U.S. Food and Drug Administration (FDA) guidance regarding manufacturing a non-antibiotic beta-lactam (ezetimibe) at the same site as ibrexafungerp. The study has resumed following the manufacture of new clinical supplies at another site and the lifting of the clinical hold by the FDA. If the study is successful and approval for this indication is granted by the FDA, it will give healthcare providers the opportunity to step-down their patients to a non-azole oral therapy that retains the Mechanism of Action (glucan synthase inhibition) of the IV-only echinocandins, which are the gold standard for treatment of invasive Candida infections. SCYNEXIS's position is that the dosing of this first new patient triggers a $10 million payment from partner GSK, with another $20 million payment to be triggered by the six-month anniversary of dosing. As previously disclosed, there is a disagreement between SCYNEXIS and GSK regarding the resumption of the MARIO Study and GSK's responsibility for paying these milestones. SCYNEXIS is working to resolve the disagreement.
SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update
JERSEY CITY, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the year ended December 31, 2024.
SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update
JERSEY CITY, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the third quarter ended September 30, 2024.
Scynexis Inc. Dividends
Scynexis Inc. Earnings
| 6 May 2025 Date | | - Cons. EPS | - EPS |
| 26 Mar 2025 Date | | - Cons. EPS | - EPS |
| 11 Nov 2024 Date | | - Cons. EPS | - EPS |
| 12 Aug 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | - Cons. EPS | - EPS |
| 6 May 2025 Date | | - Cons. EPS | - EPS |
| 26 Mar 2025 Date | | - Cons. EPS | - EPS |
| 11 Nov 2024 Date | | - Cons. EPS | - EPS |
| 12 Aug 2024 Date | | - Cons. EPS | - EPS |
| 8 Aug 2024 Date | | - Cons. EPS | - EPS |
Scynexis Inc. (SCYX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Scynexis Inc. ever had a stock split?
Scynexis Inc. Profile
| Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Dr. David Gonzalez Angulo M.D. CEO | NASDAQ (NMS) Exchange | 811292200 Cusip |
| US Country | 28 Employees | - Last Dividend | 17 Jul 2020 Last Split | 2 May 2014 IPO Date |
Overview
SCYNEXIS, Inc. is a biotechnology firm focused on the development of novel treatments for fungal infections. Based in the United States, more specifically in Jersey City, New Jersey, the company has established itself as a significant player in the industry since its inception in 1999. Originally founded as SCYNEXIS Chemistry & Automation, Inc., it underwent a name change to SCYNEXIS, Inc. in June 2002, marking a pivotal moment in its history towards a more focused biotechnological mission. SCYNEXIS, Inc. boasts a robust portfolio of collaborations with leading pharmaceutical companies such as Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC. These partnerships underscore its commitment to advancing its drug development programs, particularly for its lead candidate, ibrexafungerp, and securing its commercialization rights across various global markets.
Products and Services
BREXAFEMME: A groundbreaking product by SCYNEXIS, BREXAFEMME is approved for the treatment of vulvovaginal candidiasis (VVC), commonly known as vaginal yeast infection, as well as recurrent VVC. It represents a significant advancement in the management of these common yet often distressing conditions, offering patients a new treatment option.
Ibrexafungerp: Leading the company's product pipeline, Ibrexafungerp is an innovative intravenous drug designed to combat a broad spectrum of fungal infections. Its potential applications are wide-ranging and include the treatment of invasive candidiasis, refractory invasive fungal infections, and invasive aspergillosis, in addition to VVC and recurrent VVC. The development of Ibrexafungerp underscores SCYNEXIS's commitment to addressing unmet medical needs in the area of antifungal treatments through cutting-edge research and development.
Contact Information
